Recurrence in node-negative advanced gastric cancer with novel clinical and pathologic findings

Shangqi Chen  
Zhejiang Chinese Medical University

Can Hu  
Zhejiang Chinese Medical University

Zhiyuan Xu  
Zhejiang Cancer Hospital

Jianfa Yu  
First Affiliated Hospital of Zhejiang Chinese Medical University

Xiaofeng Wang  
Zhejiang Chinese Medical University

Hang Lv  
Key laboratory of integrated traditional chinese and western medicine for diagnosis and treatment of digestive system tumor

Shenyu Wei  
Zhejiang Chinese Medical University

Chengwei Shi  
Zhejiang Chinese Medical University

Xiangdong Cheng  (chengxd@zcmu.edu.cn)  
Zhejiang Cancer Hospital  
https://orcid.org/0000-0002-8687-8310

Research article

Keywords: Gastric cancer, Recurrence, Node-negative, Prognosis, Ki67, P53

DOI: https://doi.org/10.21203/rs.3.rs-38675/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. 
Read Full License
Abstract

Background

Node-negative gastric cancer patients carry a better prognosis than node-positive. However, a subset of these patients eventually died due to the high recurrence rate of recurrence. This study investigated the clinic-pathologic factors for recurrent patterns and prognosis.

Methods

The detailed medical records of 947 gastric cancer patients who underwent gastrectomy from the prospectively collected database of the Gastrointestinal Surgery Department of the First Affiliated Hospital of Zhejiang Chinese Medical University From January 2012 to December 2014 were analyzed retrospectively.

Results

Tumor size, tumor invasion, histological grading were the predictive factors for locoregional recurrence. Tumor invasion, histological grading, Lauren type and lymphatic vessel invasion resulted significantly in predicting peritoneal recurrence. Two parameters, tumor invasion and lymphatic vessel invasion, were significantly associated with hematogenous spread. The combinatorial biomarker of positive for both Ki67 and P53 was significantly associated with recurrence-free survival (RFS) (P = 0.037). Histological grading (P = 0.020), tumor invasion (P = 0.007) and lymphatic vessel invasion (P = 0.012) were independent factors related to overall survival (OS) in node-negative advanced gastric cancer patients.

Conclusion

The reported clinicopathologic factors for different recurrence patterns and the prognostic factors of RFS and OS should be considered to guide clinicians choose appropriate postoperative treatment strategy and construct individual follow-up schedule to improve prognosis of node-negative gastric cancer.

1 Introduction

Gastric cancer (GC) remains one of the most common malignancies in the world and accounts for the third leading cause of cancer-related deaths [1]. To date, the standard approach of radical gastrectomy is D2 lymphadenectomy for resectable advanced gastric cancer (AGC) [2]. Moreover, novel chemotherapeutic agents of improved therapeutic regimens have been used to treat this disease [3]. However, patients with AGC usually have fatal outcomes because of the high rate of recurrence [4].
Lymph node (LN) metastasis is the most significant prognostic parameter for recurrence in GC of curative resection (R0) \(^5\). Although patients with node-negative GC show an importantly better overall survival than node-positive patients, a number of these patients also experience recurrence and metastasis\(^6\). Previous reports consistently found that the depth of invasion was an independent predictor in node-negative GC that included early gastric cancer (EGC)\(^7\). Furthermore, there is no consensus about other clinicopathologic factors of the prognostic significance, including patient gender, age, tumor location, tumor size, histological grading, Lauren type and Lymphatic vessel invasion\(^8,9\). In addition, little is known about the recurrent patterns of node-negative AGC after D2 curative resection.

Nowadays, staging classification of GC has been implemented by TNM staging system. Because of the multifactorial nature of GC, TNM classification system can not guide the clinic treatment or predict the prognostic value adequately, so we need to determine the best therapeutic schedule by more instruments such as cancer biomarkers that can associate with patient survival\(^10\). It will be more appropriate that using a combination of dual cancer biomarkers to substitute for single cancer biomarker which is found to allow quantification to predict the state of GC. Several studies using combinatorial biomarkers in cervical cancer or breast cancer, but little is published in GC\(^11,12\).

On the basis of these considerations, the goals of our study are to investigate the clinic-pathologic factors of recurrence and recurrent patterns in node-negative AGC after R0 resection, and to evaluate the correlation between the outcome of these patients and predictive factors such as combinatorial cancer biomarkers.

2 Methods

2.1 Patients

We analyzed retrospectively the detailed medical records of 947 GC patients who underwent gastrectomy (R0) from the prospectively collected database of the Gastrointestinal Surgery Department of the First Affiliated Hospital of Zhejiang Chinese Medical University From January 2012 to December 2014. The inclusion criteria were as follows: (1) gastric adenocarcinoma; (2) primary AGC patients with T2, T3 or T4a stage according to the 3rd Japanese classification of gastric carcinoma\(^13\); (3) patients with more than 15 retrieved nodes after D2 gastrectomy and (4) patients with negative for metastases by routine hematoxylin-eosin staining. The exclusion criteria were as follows: (1) patients with EGC; (2) patients underwent neoadjuvant chemotherapy or post-operative radiotherapy; (3) patients with severe basic diseases such as the system problem of heart or (4) cases of operative mortality. In conformity to the eligibility criteria described above, 307 patients were enrolled in this study ultimately, including 47 patients who developed cancer recurrence (Fig. 1).

The following clinicopathologic data were obtained: age, gender, tumor location, tumor size, depth of tumor invasion(T), histological grading(G), Lauren type, lymphatic vessel invasion, adjuvant
chemotherapy, recurrence patterns (locoregional recurrence/ peritoneal seeding/ hematogenous spread) and the oncological outcomes of recurrence-free survival (RFS) and overall survival (OS).

Postoperative recurrence was diagnosed by the pieces of evidence of clinical, imaging and pathologic findings. Recurrence patterns included locoregional recurrence, peritoneal seeding and hematogenous spread. Locoregional recurrence was defined as GC tumors were detected in regional gastric nodes, gastric bed, anastomotic stoma or gastric stump. Peritoneal seeding was regarded as tumor metastasis to adjacent to the peritoneum of stomach, the region of ovary or the distant peritoneum. Hematogenous spread included cancer metastasis in viscera such as liver, brain and lung, or detected in distant lymph node.

This study, in accordance with the Declaration of Helsinki, was granted by the ethics committee of the First Affiliated Hospital of Zhejiang Chinese Medical University.

2.2 Immunohistochemical Scoring

The sections of surgical specimens were formalin-fixed and paraffin-embedded, then immunohistochemical (IHC) pathological cancer markers included P53, Ki67, HER2 were evaluated independently by two pathologists who were blinded to the information of patients. The positive immunostaining of P53 and Ki67 was expressed in nuclear staining by brown or yellow granules. P53 and Ki67 expression were graded as below: no staining observed in tumor cells or stained tumor cells < 10% in specimens were defined as negative for immunostaining and specimens in which ≥ 10% of stained tumor cells were defined as positive. The presence of HER2 was expressed by membrane staining with brownish-yellow granules. HER2 expression was scored as follows: no staining or staining in ≤ 10% of GC cells (score 0); faint/barely perceptible partial staining in > 10% (score 1+); weak-to-moderate complete staining in > 10%(score 2+) and intensely complete staining in > 10%(score 3+). Score 0 and score 1 + were graded as negative HER2 status, and score 3 + was graded as the positive status of HER2. Score 2+ had to be evaluated further by fluorescence in situ hybridization (FISH).

2.3 Follow-up

After gastrectomy, patients were followed every 3 months in the first 2 years and then every 6 months until death or, December 2018, the cut-off date of follow-up. Physical examination and hematological examination such as serum tumor marker including CEA and CA199 were performed in every visit. Chest X-rays, abdominal ultrasonography, computed tomography scans of the abdomen and gastroscopy were performed annually.

2.4 Statistical analysis

We analyzed categorical variables by the Pearson's Chi-square test or Fisher's exact test as appropriate. Patient survival data, RFS and OS, were assessed using the Kaplan–Meier method and calculated by the log-rank test to perform univariate analyses. independent prognostic factors were obtained by multivariate analyses with the Cox proportional hazards model. In this test, all P values were two-sided
and P values < 0.05 were considered statistically significant. Statistical analysis was performed with IBM SPSS Statistics for Windows, version 21.0 (IBM Corp., Armonk, NY, USA).

3 Results

3.1 Features of node-negative AGC in terms of recurrence

The clinicopathologic factors of the 307 patients with node-negative AGC are summarized in Table 1. During follow-up, 47 patients (15.3%) developed recurrence. Tumor size (P = 0.002), tumor invasion (P = 0.001), Lauren type (P = 0.038), Lymphatic vessel invasion (P = 0.015) and Ki67 expression (P = 0.034) were risk factors for recurrence of node-negative AGC, While age, gender, tumor location, histological grading, adjuvant chemotherapy, P53 expression and HER2 expression were no significant correlation observed between patients with tumor recurrence or not.
| Parameter                  | Total(307) | No(n = 260) | Yes(n = 47) | P     |
|---------------------------|------------|-------------|-------------|-------|
| Age(years)                |            |             |             | 0.227 |
| ≤ 65                      | 145        | 119         | 26          |       |
| > 65                      | 162        | 141         | 21          |       |
| Gender                    |            |             |             | 0.662 |
| Male                      | 234        | 197         | 37          |       |
| Female                    | 73         | 63          | 10          |       |
| Tumor location            |            |             |             | 0.117 |
| Upper                     | 42         | 36          | 6           |       |
| Middle                    | 108        | 87          | 21          |       |
| Lower                     | 148        | 131         | 17          |       |
| Entire                    | 9          | 6           | 3           |       |
| Tumor size                |            |             |             | 0.002 |
| ≤ 5 cm                    | 139        | 126         | 13          |       |
| > 5 cm                    | 168        | 134         | 34          |       |
| Tumor invasion(T)         |            |             |             | 0.001 |
| T2                        | 92         | 87          | 5           |       |
| T3                        | 40         | 36          | 4           |       |
| T4a                       | 175        | 137         | 38          |       |
| Histological Grading(G)   |            |             |             | 0.080 |
| G1                        | 36         | 33          | 3           |       |
| G2                        | 157        | 137         | 20          |       |
| G3                        | 114        | 90          | 24          |       |
| Lauren type               |            |             |             | 0.038 |
| Intestinal type           | 122        | 110         | 12          |       |
### Table 2

| Recurrence                     | Diffuse type | Mixed type | Lymphatic vessel invasion | Mixed type |
|-------------------------------|--------------|------------|---------------------------|------------|
| 138                           | 109          | 29         |                           |            |
| 47                            | 41           | 6          |                           |            |

| Lymphatic vessel invasion     | Positive     | Negative   | 0.015                     |
|-------------------------------|--------------|------------|---------------------------|
| 34                            | 24           | 10         |                           |
| 273                           | 236          | 37         |                           |

| Mixed type                     | Yes          | No         | 0.240                     |
|-------------------------------|--------------|------------|---------------------------|
| 230                           | 198          | 32         |                           |
| 77                            | 62           | 15         |                           |

| Mixed type                     | Positive     | Negative   | 0.060                     |
|-------------------------------|--------------|------------|---------------------------|
| 89                            | 70           | 19         |                           |
| 218                           | 190          | 28         |                           |

| Mixed type                     | Positive     | Negative   | 0.034                     |
|-------------------------------|--------------|------------|---------------------------|
| 200                           | 163          | 37         |                           |
| 107                           | 97           | 10         |                           |

| Mixed type                     | Positive     | Negative   | 0.189                     |
|-------------------------------|--------------|------------|---------------------------|
| 46                            | 36           | 10         |                           |
| 261                           | 224          | 37         |                           |

### 3.2 Pattern and incidence of recurrence

33 (70.2%) patients recurred at a single site: locoregional recurrence (n = 15, 31.9%), peritoneal seeding (n = 8, 17.0%), hematogenous metastasis (n = 10, 21.3%). 14 (29.8%) patients had recurrence at multiple sites including 1 (2.1%) patient with locoregional and peritoneal recurrence, 5 (10.6%) patients with locoregional and hematogenous recurrence, 6 (12.8%) patients with peritoneal and hematogenous recurrence, 2 (4.3%) patients with locoregional, peritoneal and hematogenous recurrence.

### 3.3 Clinicopathologic factors for different recurrence patterns

Table 2 demonstrates the correlation between the different recurrence patterns and clinicopathologic factors. Tumor size (P = 0.018), tumor invasion (P = 0.007), histological grading (P = 0.013) were the predictive factors for locoregional recurrence. Tumor invasion (P = 0.049), histological grading (P = 0.017),
Lauren type (P = 0.029) and lymphatic vessel invasion (P = 0.029) resulted significantly in predicting peritoneal recurrence. Two parameters, tumor invasion (P = 0.037) and lymphatic vessel invasion (P = 0.030), were significantly associated with hematogenous spread.
Table 2  
Clinicopathologic factors for different recurrence patterns in patients with node-negative AGC

| Parameter                  | Locoregional recurrence | Peritoneal seeding | Hematogenous spread |
|----------------------------|-------------------------|--------------------|--------------------|
|                            | Negative (n = 284)     | Positive (n = 23)  | P value            |
| Age (years)                | 0.418                   | 0.607              | 0.173              |
| ≤ 65                       | 136 9                   | 138 7              | 131 14             |
| > 65                       | 148 14                  | 152 10             | 153 9              |
| Gender                     | 0.209                   | 0.366              | 0.811              |
| Male                       | 214 20                  | 219 15             | 216 18             |
| Female                     | 70 3                    | 71 2               | 68 5               |
| Tumor location             | 0.100                   | 0.073              | 0.400              |
| Upper                      | 41 1                    | 39 3               | 38 4               |
| Middle                     | 95 13                   | 103 5              | 103 5              |
| Lower                      | 140 8                   | 141 7              | 135 13             |
| Entire                     | 8 1                     | 7 2                | 8 1                |
| Tumor size                 | 0.018                   | 0.064              | 0.137              |
| ≤ 5 cm                     | 134 5                   | 135 4              | 132 7              |
| > 5 cm                     | 150 18                  | 155 13             | 152 16             |
| Tumor invasion (T)         | 0.007                   | 0.049              | 0.037              |
| T2                         | 89 3                    | 91 1               | 90 2               |
| T3                         | 40 0                    | 38 2               | 37 3               |
| T4a                        | 155 20                  | 161 14             | 157 18             |
### 3.4 Prognostic factors of RFS and OS

| Parameter | Locoregional recurrence | Peritoneal seeding | Hematogenous spread |
|-----------|-------------------------|--------------------|---------------------|
|           | Negative (n = 284) Positive (n = 23) | Negative (n = 290) Positive (n = 17) | Negative (n = 284) Positive (n = 23) |
| Histological grading (G) | | | |
| G1 | 34 2 | 35 1 | 34 2 |
| G2 | 151 6 | 153 4 | 146 11 |
| G3 | 99 15 | 102 12 | 104 10 |
| Lauren type | | | |
| Intestinal type | 116 6 | 120 2 | 115 7 |
| Diffuse type | 124 14 | 127 11 | 123 15 |
| Mixed type | 44 3 | 43 4 | 46 1 |
| Lymphatic vessel invasion | | | |
| Positive | 30 4 | 29 5 | 28 6 |
| Negative | 254 19 | 261 12 | 256 17 |
| Adjuvant chemotherapy | | | |
| Yes | 212 18 | 220 10 | 215 15 |
| No | 72 5 | 70 7 | 69 8 |
In regard to RFS, Kaplan-Meier survival curves and the log-rank test showed that histological grading (P = 0.029), tumor invasion (P = 0.011) had significantly worse prognosis. Then the significant prognostic parameters (p < 0.1) were enrolled in the Cox proportional hazards model. Only tumor invasion (P = 0.009) as an independent factor for RFS in node-negative AGC patients. In terms of OS, there were significant relationship with tumor size (P = 0.045), histological grading (P = 0.031), tumor invasion (P = 0.008) and lymphatic vessel invasion (P = 0.024) by the univariate analysis. The multivariate analysis indicated that histological grading (P = 0.020), tumor invasion (P = 0.007) and lymphatic vessel invasion (P = 0.012) were independent factors related to OS.

According to the expression of Ki67 and P53, we divided the 307 patients into three groups: Group1 (negative for both Ki67 and P53, n = 94), Group2 (positive for either Ki67 or P53, n = 153), Group3 (positive for both Ki67 and P53, n = 60). Group3 had shorter RFS (P = 0.006) by univariate analysis and shorter RFS (HR, 1.516; 95% CI, 1.251–1.837; P = 0.037) by multivariate analysis in comparison with Group1 and Group2. However, the Group3 was no an independent parameter for OS. (Table 3)
| Prognostic factor | RFS univariate analysis | RFS multivariate analysis | OS univariate analysis | OS multivariate analysis |
|------------------|------------------------|--------------------------|-----------------------|-------------------------|
|                  | P value                | HR                       | 95% CI                | P value                |
| Ki67/P 53 expression (Group1/Group2 vs. Group3) | 0.006 | 1.516 | 1.251–1.837 | 0.037 | 0.083 | 2.007 | 0.929–4.336 | 0.037 |
| Tumor size (≤ 5 cm vs. > 5 cm) | 0.132 | 0.045 | 1.013 | 0.775–1.324 | 0.082 |
| Histological grading (G1/G2 vs. G3) | 0.029 | 1.143 | 0.823–1.587 | 0.068 | 0.031 | 1.579 | 1.217–2.049 | 0.020 |
| Tumor invasion (T) (T2/3 vs. T4a) | 0.011 | 1.994 | 1.533–2.593 | 0.009 | 0.008 | 2.162 | 1.340–3.488 | 0.007 |
| Lymphatic vessel invasion (Negative vs. Positive) | 0.095 | 1.129 | 0.750–1.700 | 0.190 | 0.024 | 1.717 | 1.302–2.264 | 0.012 |
| Adjuvant chemotherapy |                  |                          |                        |                         |
| Prognostic factor | RFS univariate analysis | RFS multivariate analysis | OS univariate analysis | OS multivariate analysis |
|------------------|------------------------|--------------------------|-----------------------|-------------------------|
|                  | P value     HR  95% CI | P value     HR  95% CI | P value     HR  95% CI | P value     HR  95% CI |
| (Negative vs. Positive) | 0.830       0.504      |                         |                       |

Figure 2 demonstrated that the RFS (P = 0.002) and the OS (P = 0.030) of Group3 had significantly worse to Group1 respectively.

4 Discussion

Although the incidence of gastric cancer was gradually decreased year by year, gastric cancer is still the third leading cause of cancer-related deaths all over the world because of poor biological behavior. Node-negative GC patients carry a significantly better prognosis than node-positive GC. However, a subset of these patients eventually died due to recurrence. Chou et al. reported the cumulative RFS rate and OS rate were 83.2% and 84.3%, respectively, in node-negative AGC patients underwent gastrectomy (R0) at five-year\[14\]. Correspondingly, Zhao et al. investigated the cumulative RFS rate and OS rate were 71.1% and 63.5%, respectively\[15\]. In the present study, With the median follow-up period of 57.5 months, 47 (15.3%) of 307 patients had tumor recurrences. The entire 307 patients with node-negative AGC who underwent D2 lymphadenectomy with the cumulative RFS rate and OS rate were 84.9% and 77.2% at five-year, respectively. In consideration of the high recurrence rate for node-negative AGC and the situation that these patients lacking independent prognosis factors except for the depth of invasion, it is necessary to find predictive outcome indicators that may complement TNM staging system and guide clinicians not only to choose appropriate postoperative treatment strategy but also to construct individual follow-up schedule to improve prognosis of GC\[6, 16\].

In this study, we excluded patients with T1 and T4b stage, on account of early gastric cancer (T1N0) associated with favorable prognosis who had low lymph node metastatic rate. On the contrary, T4b patients who had lower 5-year survival rate usually received postoperative chemotherapy by reason of the malignant biological behavior of gastric cancer\[17\]. To some extent, it can reduce their confounding effect in the research.

Implementing appropriate adjuvant therapy is vital for gastric cancer patients after complete tumor resection to prevent recurrence and improve overall survival. Sasako et al. reported the adjuvant chemotherapy of S-1 can prolong curatively resected GC patients’ overall survival. Combination of fluoropyrimidines and platinum is remaining the first line treatment of AGC\[18\]. Sakamoto et al. put forward capecitabine plus cisplatin were effective to patients with early relapse\[19\]. The 1-year RFS rates
of stage II patients (n = 41) and stage III patients (n = 59) were 87% and 84% respectively found in JCLASSIC-PII. In conclusion, capecitabine plus oxaliplatin was beneficial following resection of GC in Japanese patients[20]. However, we didn't find that a statistically significant association between improved prognosis and postoperative chemotherapy. Although 230 patients (74.9%) were received chemotherapy, only 148 patients (64.3%) patients finished > 80% of the scheduled cycles, the other patients owing to the side effects of the chemotherapy and economic reasons didn’t receive chemotherapy or complete it, which might affect the conflicting results.

Of note, different patterns of recurrence correspond to different postoperative adjuvant therapy regimens. Hence, it is significant to predict the recurrence pattern to scheme personalized therapy[21]. Previously, Huang et al. reviewed the medical records of 317 node-negative GC patients and the results showed that 51 patients had recurred, the population patients with locoregional recurrence, peritoneal seeding accounted for 51.0% separately and 21 (41.1%) patients had hematogenous metastasis[15]. Chou et al. indicated that the main pattern of recurrence in node-negative patients was locoregional disease[14]. This study is not in accordance with previous results that the main pattern were locoregional (n = 28, 48.9%) and hematogenous (n = 28, 48.9%) recurrence. This difference might be out of with/without receiving chemotherapy after surgery, regional difference and the variability of tumor biology. Tumor size, the depth of tumor invasion (T stage), Lauren type and the presence of lymphatic vessel invasion have been identified as risk factors for recurrence in this series[22]. Furthermore, we demonstrated that tumor size, T stage and histological differentiation were significant risk indicators for locoregional recurrence in node-negative GAC. T stage, tumor differentiation, Lauren type and lymphatic vessel invasion were associated with higher risks of peritoneal seeding. Of these factors, the depth of tumor invasion and the presence of lymphatic vessel invasion were relevant to hematogenous spread. Actually, in regard to the predictors of recurrence patterns in GC have been explored previously, but few in node-negative[23–25]. Interestingly, pT stage had been confirmed as a risk predictor in any of recurrence patterns in relevant research fields[26, 27]. The depth of tumor invasion was also the most unanimous significant prognostic parameter of node-negative GC patients, which was consistent with the multivariate analysis (P = 0.007) of independent factors related to OS in this study. In the aspect of tumor size, it is no consistency for the prognostic significance in node-negative AGC, unlike breast and lung cancer[28, 29]. Chou et al. demonstrated that bigger tumor was correlated with hematogenous metastasis, but we only observed tumor size was related to Locoregional recurrence[14]. The discrepancy may be explained by enrolling T4b patients who had dismal prognosis in their research that was not included ours. Although several studies found tumor size increased the hazard for recurrence and survival in advanced node-negative GC underwent R0 resection, this result was not repeated in other researches[30–32]. Univariate analysis revealed tumor size was significantly associated with 5-year OS (P = 0.045) in our series but it lost any significance in the multivariate analysis with the Cox proportional hazards model (P = 0.082). In terms of the presence of lymphatic vessel invasion, it was a predictive marker both for peritoneal seeding and hematogenous spread. On the other hand, it was an important poor prognostic indicator to shorten the time of OS. Noteworthily, The above results of lymphatic vessel invasion were consistent with this study. Zhao et al.
hypothesized lymphatic vessel invasion was the startup phase based on it was associated with lymph node micrometastasis\textsuperscript{[15]}. Unfortunately, we have not observed it had prognostic value in recurrence-free survival.

In general, the combined use of the pathological cancer markers, has more complex and more heterogeneous, might has more advantages than that of single markers for GC patients in the prognostic value. p53 is a tumor-suppressor gene that located on chromosome 17p and encoded a 53-kDa protein\textsuperscript{[33]}. The p53 gene plays an important role in the cell cycle by G1 arrest checkpoint cell cycle to modulate cell proliferation and suppress the development of tumor\textsuperscript{[34]}. However, during the development of GC, the functions of p53 protein are often blocked because it has undergone mutation. Compare to normal p53 protein, mutated p53 protein prolong its half-life on account of changing configuration and increasing stability. Therefore, it can be detected by immunohistochemical staining. Several studies have reported that overexpression of p53 were independent risk factors for EGC patients\textsuperscript{[35, 36]}. Ki67 is a nuclear proliferation-associated antigen, which encodes two protein isoforms with molecular weights of 345 and 395 kDa. In addition, it is universally expressed throughout the cell cycle in proliferating (late G1, S, G2 and M-phases), but is absent in quiescent cells\textsuperscript{[37]}. The prognostic value of pKi67 has been investigated as a reliable marker having been shown in several types of cancer, such as colorectal and breast cancer, according to activating the trigger of downregulation for the gene of apoptosis\textsuperscript{[38, 39]}. Whereas, some analyses found the expression of Ki67 was correlated with survival in gastric cancer, others found no significant difference between Ki67 expression and oncological outcomes\textsuperscript{[40, 41]}. In a word, p53 and Ki67 are important biomarkers for cancer progression. However, little research reported on whether the combination of p53 and Ki67 is an independent prognosis factor in node-negative AGC after D2 curative resection. The whole patients were divided into 3 groups: Group1 (negative for both Ki67 and P53), Group2 (positive for either biomarker), Group3 (positive for both biomarkers). We found Group3 was a significant prognostic parameter in terms of RFS and OS compared with Group1, $P = 0.002$ and $P = 0.030$ respectively. Meanwhile, Group 3 had shorter recurrence-free survival compared with Group1 and Group2 in the multivariate analysis with the Cox proportional hazards model ($P = 0.037$), but do not find the significant difference between Group 3 and OS.

Several limitations of the present study should be acknowledged. Firstly, on account of the retrospective nature of this study, all the result may be influenced. Secondly, it was single institutional research with the limitation of the number of patients. On the side, our observations are necessary to be confirmed by more large-scale prospective studies with more longer follow-up time.

## 5 Discussion

The data presented in this report demonstrate that tumor size, tumor invasion and histological grading resulted significantly in predicting locoregional recurrence with node-negative AGC after D2 curative resection. Tumor invasion, histological grading, Lauren type and lymphatic vessel invasion were the predictive factors for peritoneal recurrence. Tumor invasion and lymphatic vessel invasion were
significantly associated with hematogenous spread. The combinatorial biomarker of positive for both Ki67 and P53, histological grading, tumor invasion and lymphatic vessel invasion were independent factors related to prognosis.

**Abbreviations**

GC
Gastric cancer; AGC: Advanced gastric cancer; LN: Lymph node; R0: Curative resection; EGC: Early gastric cancer; T: Depth of tumor invasion; G: Histological grading; RFS: Recurrence-free survival; OS: Overall survival; IHC: Immunohistochemical; FISH: Fluorescence in situ hybridization

**Declarations**

**Availability of data and materials**

The clinical datasets supporting the results of this article are available from the corresponding author.

**Ethics approval and consent to participate**

The study was conducted with strict adherence to the Declaration of Helsinki. The study protocol was reviewed and approved by the ethics committee of the First Affiliated Hospital of Zhejiang Chinese Medical University. Informed consent to participate this study was obtained from all patients in writing or orally. The procedure for oral consent was approved by the ethics committee.

**Consent for publication**

Not applicable.

**Competing interests**

The Authors declare no conflict of Interest exists in regard to this study.

**Funding**

This work was supported by the Major Science and Technology Project of Zhejiang Province of China (Grant No. 2019C03049); Natural Science Foundation of Zhejiang Province (Grants no. LY18H290006; Traditional Chinese Medicine Scientific Research Foundation of Zhejiang Province (Grant no. 2019ZZ010, 2018ZY006); National Natural Science Foundation of China (Grant No. 81573953); Zhejiang Provincial Medical and Healthy Science and Technology Projects (Grants No. 2016KYB220)

**Authors’ contributions**
CSQ, HC, XZY, and CXD designed the study. CSQ, XZY, HC, YJF, and WXF performed data acquisition and analysis. CSQ, XZY, HC, LH, WSY, and SCW performed statistical analysis and data interpretation. CSQ prepared the manuscript. All authors read and approved the final manuscript.

**Acknowledgements**

Not applicable.

**References**

1. Emadi-Baygi M, Sedighi R, Nourbakhsh N, et al. Pseudogenes in gastric cancer pathogenesis: a review article. Brief Funct Genomics. 2017;16:348–60.

2. Datta J, McMillan MT, Ecker BL, et al. Implications of Lymph Node Staging on Selection of Adjuvant Therapy for Gastric Cancer in the United States: A Propensity Score-matched Analysis. Ann Surg. 2016;263:298–305.

3. Xin J, Wang S, Wang J, et al. Nanosystem Integrated with Photosensitizer and Novel Targeting Chemotherapy Agent for Gastric Cancer Chemo-Photodynamic Combined Therapy. J Biomed Nanotechnol. 2018;14:1430–47.

4. Kang WM, Meng QB, Yu JC, et al. Factors associated with early recurrence after curative surgery for gastric cancer. World J Gastroenterol. 2015;21:5934–40.

5. Jin EH, Lee DH, Jung SA, et al. Clinicopathologic factors and molecular markers related to lymph node metastasis in early gastric cancer. World J Gastroenterol. 2015;21:571–7.

6. Baiocchi GL, Molino S, Baronchelli C, et al. Recurrence in node-negative advanced gastric cancer: Novel findings from an in-depth pathological analysis of prognostic factors from a multicentric series. World J Gastroenterol. 2017;23:8000–07.

7. Bruno L, Nesi G, Montinaro F, et al. Clinicopathologic characteristics and outcome indicators in node-negative gastric cancer. J Surg Oncol. 2000;74:30–2.

8. Zhou Y, Yu F, Wu L, et al. Survival after Gastrectomy in Node-Negative Gastric Cancer: A Review and Meta-Analysis of Prognostic Factors. Med Sci Monit. 2015;21:1911–9.

9. Jeong JY, Kim MG, Ha TK, et al. Prognostic factors on overall survival in lymph node negative gastric cancer patients who underwent curative resection. J Gastric Cancer. 2012;12:210–6.

10. min KW, Kim, Son DH. B K, et al. A High Ki67/BCL2 Index Could Predict Lower Disease-Free and Overall Survival in Intestinal-Type Gastric Cancer. Eur Surg Res. 2017;58:158–68.

11. Ali HR, Dawson SJ, Blows FM, et al. A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer. J Pathol. 2012;226:97–107.

12. Park S, Eom K, Kim J, et al. MiR-9, miR-21, and miR-155 as potential biomarkers for HPV positive and negative cervical cancer. BMC Cancer. 2017;17:658.

13. Japanese classification of gastric carcinoma. 3rd English edition. Gastric Cancer. 2011;14:101–12.
14. Chou HH, Kuo CJ, Hsu JT, et al. Clinicopathologic study of node-negative advanced gastric cancer and analysis of factors predicting its recurrence and prognosis. Am J Surg. 2013;205:623–30.
15. Zhao B, Huang X, Zhang J, et al. Clinicopathologic factors associated with recurrence and long-term survival in node-negative advanced gastric cancer patients. Rev Esp Enferm Dig. 2019;111:111–20.
16. Huang CM, Lin JX, Zheng CH, et al. Prognostic impact of dissected lymph node count on patients with node-negative gastric cancer. World J Gastroenterol. 2009;15:3926–30.
17. Zhu BY, Yuan SQ, Nie RC, et al. Prognostic Factors and Recurrence Patterns in T4 Gastric Cancer Patients after Curative Resection. J Cancer. 2019;10:1181–88.
18. Ito S, Ohashi Y, Sasako M. Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial. BMC Cancer. 2018;18:449.
19. Nishikawa K, Tsuburaya A, Yoshikawa T, et al. A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial. Gastric Cancer. 2018;21:811–18.
20. Kim R, Tan A, Choi M, et al. Geographic differences in approach to advanced gastric cancer: Is there a standard approach? Crit Rev Oncol Hematol. 2013;88:416–26.
21. Li GC, Zhang Z, Ma XJ, et al. Are biomarkers correlated with recurrence patterns in patients with resectable gastric adenocarcinoma. Mol Biol Rep. 2012;39:399–405.
22. Huang KH, Chen JH, Wu CW, et al. Factors affecting recurrence in node-negative advanced gastric cancer. J Gastroenterol Hepatol. 2009;24:1522–6.
23. Lee JH, Chang KK, Yoon C, et al. Lauren Histologic Type Is the Most Important Factor Associated With Pattern of Recurrence Following Resection of Gastric Adenocarcinoma. Ann Surg. 2018;267:105–13.
24. Tanaka H, Kanda M, Miwa T, et al. Pattern-Specific Transcriptomics Identifies ASGR2 as a Predictor of Hematogenous Recurrence of Gastric Cancer. Mol Cancer Res. 2018;16:1420–29.
25. Wu J, Liu X, Cai H, et al. Prediction of tumor recurrence after curative resection in gastric carcinoma based on bcl-2 expression. World J Surg Oncol. 2014;12:40.
26. Lee IS, Yook JH, Kim TH, et al. Prognostic factors and recurrence pattern in node-negative advanced gastric cancer. Eur J Surg Oncol. 2013;39:136–40.
27. He H, Shen Z, Wang X, et al. Survival benefit of greater number of lymph nodes dissection for advanced node-negative gastric cancer patients following radical gastrectomy. Jpn J Clin Oncol. 2016;46:63–70.
28. Weigelt B, Peterse JL, van ’t Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5:591–602.
29. Tomizawa K, Shimizu S, Ohara S, et al. Clinical significance of tumor cavitation in surgically resected early-stage primary lung cancer. Lung Cancer. 2017;112:57–61.
30. Zhou Y, Cui JG, Huang F, et al. Prognostic Factors for Survival in Node-Negative Gastric Cancer Patients Who Underwent Curative Resection. Scand J Surg. 2017;106:235–40.
31. Dittmar Y, Schule S, Koch A, et al. Predictive factors for survival and recurrence rate in patients with node-negative gastric cancer—a European single-centre experience. Langenbecks Arch Surg. 2015;400:27–35.

32. Liu X, Cai H, Shi Y, et al. Prognostic factors in patients with node-negative gastric cancer: a single center experience from China. J Gastrointest Surg. 2012;16:1123–7.

33. Zedan W, Mourad MI, El-Aziz SM, et al. Cytogenetic significance of chromosome 17 aberrations and P53 gene mutations as prognostic markers in oral squamous cell carcinoma. Diagn Pathol. 2015;10:2.

34. Mai W, Liu H, Chen H, et al. RGNNV-induced cell cycle arrest at G1/S phase enhanced viral replication via p53-dependent pathway in GS cells. Virus Res. 2018;256:142–52.

35. Goncalves AR, Carneiro AJ, Martins I, et al. Prognostic significance of p53 protein expression in early gastric cancer. Pathol Oncol Res. 2011;17:349–55.

36. Zhou F, Xu Y, Shi J, et al. Expression profile of E-cadherin, estrogen receptors, and P53 in early-onset gastric cancers. Cancer Med. 2016;5:3403–11.

37. Singh S, Hallet J, Rowsell C, et al. Variability of Ki67 labeling index in multiple neuroendocrine tumors specimens over the course of the disease. Eur J Surg Oncol. 2014;40:1517–22.

38. Melling N, Kowitz CM, Simon R, et al. High Ki67 expression is an independent good prognostic marker in colorectal cancer. J Clin Pathol. 2016;69:209–14.

39. Healey MA, Hirko KA, Beck AH, et al. Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nurses’ Health Study. Breast Cancer Res Treat. 2017;166:613–22.

40. Boger C, Behrens HM, Rocken C. Ki67–An unsuitable marker of gastric cancer prognosis unmasks intratumoral heterogeneity. J Surg Oncol. 2016;113:46–54.

41. Wu HW, Qin CY, Huang JL, et al. Correlations of beta-catenin, Ki67 and Her-2/neu with gastric cancer. Asian Pac J Trop Med. 2014;7:257–61.

Figures
Figure 1

Flow chart of the inclusion process for eligible patients in this study.
Figure 2

Recurrence-free survival curves (a) and overall survival curves (b) for node-negative AGC patients in combination with p53 and Ki67 expression (Group1-3).
Figure 3

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- coverletter.doc